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Sir: As an immune escape mechanism, tumour cells
may down-regulate expression of human leucocyte
antigens (HLA). Loss of HLA classes I and II has been
described in various subtypes of diffuse large B cell
lymphoma (DLBCL), including the not otherwise spec-
ified (NOS) subgroup.1,2 We analysed HLA classes I
and II expression in DLBCL-NOS to investigate
whether there is an association between HLA expres-
sion, cell of origin (COO) and the recently reported
FoxP1 expression in non-GCB DLBCL.3
Seventy-seven cases of DLBCL-NOS with an almost
exclusively nodal presentation were classified for COO
by immunohistochemistry (IHC) according to the
Hans algorithm as germinal centre B (GCB) cell-type
(n = 42) or non-GCB-type (n = 35) (Table 1). Clinical
data available from 67 cases indicated a histologically
confirmed pre-existent or concurrent indolent lym-
phoma in 16 patients, i.e. 13 follicular lymphoma,
two marginal zone lymphoma and one chronic lym-
phocytic leukaemia. Expression of HLA and FoxP1
was assessed by IHC; methods are described in the
Supporting Information.
Significant differences (P < 0.01) in HLA loss were
observed between the COO categories in the total
group: loss of HLA class I in 51% of non-GCB versus
21% of GCB, of HLA class II in 37% of non-GCB ver-
sus 10% of GCB and combined loss in 34% of non-
GCB versus 5% of GCB (Figure 1A).
In the total group, 35% of the cases showed loss of
HLA class I expression, 22% showed loss of HLA class
II and 18% showed loss of both, whereas 25%
retained expression of both HLA classes I and II. Two
lymphomas with partial loss of HLA class I and two
other lymphomas with partial loss of HLA class II
were considered HLA-negative.
In 51 de-novo cases loss of HLA class I was
observed in 21 (41%) and loss of HLA class II in 16
(31%) cases. In 16 transformed cases, expression of
HLA class I was lost in 5 (31%; Figure S2), two cases
of which showed additional loss of class II (13%). As
transformation from follicular lymphoma is associated
with the GCB-type, we studied GCB-type DLBCL sepa-
rately, and found loss of HLA class I in five of 14
transformed cases (36%) versus four of 28 de-novo
GCB cases (14%) (P = 0.13). In consequence, the dif-
ferences for HLA class I between the COO subtypes
were even more pronounced after exclusion of trans-
formed cases: 55% of non-GCB versus 14% of GCB
cases showed loss of expression (P ≤ 0.01). Thus,
Table 1. Features of DLBCL-NOS cases
Characteristic Non-GCB (35) GCB (42) P-value
Male (%) 23 (66) 24 (57)
Median age
(years; range)
66 (9–85) 56 (14–77)
Ann Arbor stage
I/II (%) 6 (17) 18 (43)
III/IV (%) 26 (74) 18 (43)
Unknown (%) 3 (9) 6 (14)
IPI
0–1 (%) 5 (14) 13 (31)
2–3 (%) 19 (55) 18 (43)
4–5 (%) 7 (20) 1 (2)
Unknown (%) 4 (11) 10 (24)
Transformation* (%) 2 (6) 14 (33) <0.01
HLA class I+ (%) 17 (49) 33 (79) <0.01
HLA class I (%) 17 (49) 8 (19)
Partial loss
HLA class I (%)
1 (2) 1 (2)
HLA class II+ (%) 22 (63) 38 (91) <0.01
HLA class II (%) 12 (34) 3 (7)
Partial loss HLA
class II (%)
1 (3) 1 (2)
Double-negative (%) 12 (34) 2 (5) <0.01
FoxP1 ≥ 80%+/
evaluable cases (%)
18/26 (69) 16/35 (46) 0.08
IPI, International Prognostic Index; HLA, Human leucocyte antigen;
FoxP1, Forkhead box protein 1; GCB, Germinal centre B cell;
DLBCL-NOS, Diffuse large B cell lymphoma, not otherwise
specified.
*Transformation from a pre-existent or concurrent indolent lym-
phoma; see text.
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these results were not influenced by the inclusion of
16 cases with a history of follicular lymphoma or
other types of indolent lymphoma which, in line with
the literature, were almost exclusively of GCB-type.
Brown et al. suggested that FoxP1, a protein associ-
ated with non-GCB-type DLBCL, is related inversely
with HLA class II expression.4 A high expression of
FoxP1 with a low expression of HLA class II expres-
sion was observed in normal pre-plasma cells and
non-GCB-type DLBCL maturing to plasmablasts.5 This
is in line with data from the group of Rimsza et al.,
suggesting that loss of HLA class II is seen in DLBCL
cases maturing into plasmablastic lymphoma.2,6 We
studied the correlation between FoxP1 expression and
HLA class II expression in 61 DLBCL cases (Fig-
ures S1 and S3). FoxP1 expression was not associ-
ated significantly with non-GCB-type DLBCL (Table 1;
P = 0.08). We did not find an association between
FoxP1 and HLA class II expression: loss of HLA class
II was associated very weakly with FoxP1 expression
in both non-GCB- and GCB-type DLBCL. However, the
majority of cases retained HLA class II expression
while expressing high FoxP1 levels in both categories
and vice versa; not all cases with low HLA class II
showed high FoxP1 expression (Figure 1B,C). Of note,
high expression of FoxP1 and HLA class II expression
were excluded from analysis in the original study.4
Furthermore, while most FoxP1-positive cases showed
homogeneous staining of the tumour cells and only a
few cases showed partial loss of HLA class II expres-
sion, a qualitative (intensity of staining) analysis of
both proteins is not accomplished easily by immuno-
histochemistry.
In conclusion, we show that loss of HLA class I
and/or HLA class II, in particular the double-negative
signature, is much more common in non-GCB-type
DLBCL than in GCB-type DLBCL. Our data support
previous reports, focusing on class II expression.6 The
preferential loss of HLA class II expression in non-
GCB-type DLBCL cannot be explained by a higher
expression of FoxP1 alone.
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Figure 1. Difference in loss of human leucocyte antigen (HLA) class I and HLA class II between non-germinal centre B cell (GCB) and GCB
diffuse large B cell lymphoma (DLBCL). A, Percentage of HLA class I and II negative cases in non-GCB and GCB DLBCL and double-negative
cases; B, percentage of FoxP1 positive and negative cases in HLA class II negative and positive non-GCB DLBCL cases; C, percentage of
FoxP1 positive and negative cases in HLA class II negative and positive GCB-type DLBCL.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Data S1. Methods.
Figure S1. Percentage of FOXP1 positive cells. A
cut-off of ≥80% was used as in the literature,4 since
most cases were below 20% or 80% and higher.
Figure S2. HLA class I expression in a single case
with DLBCL and co-existent follicular lymphoma (FL).
The DLBCL shows loss of expression while the FL
shows retained expression.
Figure S3. FoxP1 expression.
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